Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Brandon Capital Partners is a venture capital firm founded in 2007 and headquartered in Melbourne, Australia, with additional offices in Sydney, London, and San Francisco. The firm has raised over A$1 billion across six funds and manages a fund size of $290 million. They have a portfolio of 90 companies, with an active focus on over 30.
Brandon Capital invests between $500K and $10M in early-stage biomedical innovations, including pharmaceuticals, biotechnology, healthcare devices, and digital health. Their investment strategy spans from proof-of-concept to commercialization stages, supporting companies that aim to improve patient outcomes.
Notable companies in Brandon Capital's portfolio include Ena Respiratory, NRG Therapeutics, Vaxxas, and Myricx Bio. The firm has achieved 1 IPO and 7 acquisitions, with 17 companies currently in clinical trials.
Submit your pitch through their form at brandoncapital.vc or email info@brandoncapital.com.au with your deck.
As of October 22, 2025, Brandon Capital made 5 investments in the last 12 months, indicating active engagement in the life sciences sector.
Yes, Brandon Capital often leads investment rounds, particularly in early-stage life sciences companies.
The firm actively participates in follow-on investments to support portfolio companies through their growth stages.
Brandon Capital currently manages a fund size of $290 million, focusing on life sciences investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.